
PATENT COOPERATION TREATY

PCT



INTERNATIONAL PRELIMINARY REPORT ON PATENTABILITY (Chapter II of the Patent Cooperation Treaty)

(PCT Article 36 and Rule 70)

Applicant's or agent's file reference	1					
04P400146	FOR FURTHER ACTION See Form PCT/IPEA/416					
International application No.	International filing of	late (day/month/year)	Priority date (day/month/year)			
		2004(13.07.04)	16.Jan.2004(16.01.04)			
International Patent Classification (IPC) or	national classification	and IPC				
IPC ⁷ :A61K9/127,38/21,A61P31/12						
Applicant						
SHENZHEN NEPTUNUS IN	TERLONG BIO-TEC	HNIQUE HOLDINGS CO.	,LTD. etal.			
	nary examination ren	ort established by this Inter-	national Preliminary Examining Authority			
2. This REPORT consists of a total of	3	sheets, including this	cover sheet.			
3. This report is also accompanied by AN	NEXES, comprising:					
 a. (sent to the applicant and to the International Bureau) a total of 1 sheets, as follows: sheets of the description, claims and/or drawings which have been amended and are the basis of this report and/or sheets containing rectifications authorized by this Authority (see Rule 70.16 and Section 607 of the Administrative Instructions). 						
sheets which supersede earlier sheets, but which this Authority considers contain an amendment that goes beyond the disclosure in the international application as filed, as indicated in item 4 of Box No. I and the Supplemental Box.						
b. (sent to the International Bureau only) a total of (indicate type and number of electronic containing a sequence listing and/or tables related thereto, in electronic form only, as indicated in the Supplemental Box Relating to Sequence Listing (see Section 802 of the Administrative Instructions).						
Box No. I Basis of the rep	ort					
☐ Box No. II Priority			i			
		gard to novelty, inventive ste	p and industrial applicability			
☐ Box No. IV Lack of unity of						
⊠ Box No. V Reasoned statement	nt under Article 35(2)	with regard to novelty, inve	entive step or industrial applicability;			
	anations supporting su	ich statement				
Box No. VI Certain document						
	the international app					
	ions on the internation	nal application				
Date of submission of the demand		Date of completion of this report				
06.Apr.2005(06.04.2002)		19.Apr.2005(19.04.2005)				
Name and mailing address of the IPEA/CN The State Intellectual Property Office, 6 Xitucheng Rd., Jimen Bridge, Haid Beijing, 100088, China	dian District,	Authorized officer				
Facsimile No. 86-10-62019451		Telephone No. 86-10-62	085232			

INTERNATIONAL PRELIMINARY REPORT ON PATENTABILITY

International application No. PCT/CN2004/000803

Box			of the report				
1.	Wi	th regard to	the language, this report is based on:				
	\boxtimes	the international application in the language in which it was filed					
		a transla	tion of the international application into,	which is the language of a			
		translation	1 furnished for the purposes of:	guuge of u			
			ational search (Rules 12.3(a) and 23.1(b))				
	□publication of the international application (Rule 12.4(a))						
			ational preliminary examination (Rules 55.2(a) and/or 55.3(a))				
			(Rules 55.2(a) and/or 55.5(a))				
2.	to t	th regard to he receiving nexed to this	the elements of the international application, this report is based on (replaceme coeffice in response to an invitation under Article 14 are referred to in this report):	nt sheets which have been furnished rt as "originally filed" and are not			
	\boxtimes		ational application as originally filed/furnished				
	\boxtimes	the descri	ption:				
		pages	1-12	as originally filed/furnished			
		pages *	received by this Authority on				
		pages *	received by this Authority on				
	\boxtimes	the claims:	•				
	_	pages	2	og originally filed/formisk - d			
		pages *		as originally filed/furnished with any statement)under Article 19			
		pages *	1 received by this Authority or	· · · · · · · · · · · · · · · · · · ·			
		pages *	received by this Authority or				
Г		the drawing pages pages pages a sequence	received by this Authority on received by this Authority on listing and/or any related table(s) - see Supplemental Box Relating to Sequence	_ as originally filed/furnished			
3. [⊽ 1		ments have resulted in the cancellation of:	Listing.			
J. ½	<u> </u>						
			description, pages				
			claims, Nos. 2				
			drawings, sheets/figs				
			sequence listing (specify):				
		☐ any	table(s) related to sequence listing (specify):				
4. [] :	the c	has been established as if (some of) the amendments annexed to this report and I have been considered to go beyond the disclosure as filed, as indicated in the Sulescription, pages	applemental Box (Rule 70.2(c)).			
			lrawings, sheets/figs				
			sequence listing (specify):				
			table(s) related to sequence listing (specify):				
*	If i	tem 4 applie	es, some or all of those sheets may be marked "superseded."				

INTERNATIONAL PRELIMINARY REPORT ON PATENTABILITY

International application No. PCT/CN2004/000803

Box No. V Reasoned statement under Article 35(2) with regard to novelty, inventive step or industrial applicability; citations and explanations supporting such statement				
1. Stateme	ent:			
N	ovelty (N)	Claims	1-11	YES
		Claims		NO
In	ventive step (IS)	Claims	4-11	YES
		Claims	1-3	NO
Ind	ustrial applicability (IA)	Claims	1-11	YES
		Claims		NO

- 2. Citations and explanations (Rule 70.7)
 - 1). The application claims a cream that contains interferon liposome.
 - 2). The closest document in the international search report is as follows:
 - D1: US5853755A(PHARMADERM LABORATORIES LTD.)
- D1 disclosed a dermal formulation containing interferon liposome such as cream(for example. see the column 7, lines 4-10), wherein the membrance material was composed of phospholipid and the like. The amounts of the active ingredient between claim 1 and D1 are different, but on the basis of D1, it is obvious for the skilled person in the art to obtain the claims 1-3 with the aid of knowledge in the art. Therefore, claims 1-3 meet the requirement of Art.33(2), but they lack the inventive step of Art.33(3.)
- 3).D1 gave the instruction that interferon could be formulated into liposome for dermal use and some embodiments, but it didn't give the same embodiments as claims 4-11 or the suggestion of them, and claims 4-11 therefore meet the requirement of novelty of Art.33(2) and that of inventive step of Art.33(3).
- 4). Claims 1-11 can be easily carried out in the pharmaceutical industry, thus they meet the requirement of in industrial applicability of Art.33(4).